CORDIS · 293476 · FP7
EGCG+INSULIN= Towards construction of a comprehensive map of amyloid-ligand interactions: (-)-Epigallocatechin 3-Gallate and insulin amyloid
Coordinator: VILNIAUS UNIVERSITETAS (LT)
Increasing number of peptides and proteins are found to form ordered fibrillar aggregates under certain conditions. Amyloid-like fibrils are associated with a number of diseases, ranging from neurodegenerative diseases to systemic amyloidoses. Current studies have shown the ability of (-)-Epigallocatechin 3-Gallate (EGCG) to inhibit fibril formation and even to dissociate fibrils. Nevertheless, some EGCG-resistant structures were also reported. To evaluate EGCG as a possible drug candidate against amyloid diseases, extensive studies of protein aggregation in presence of the ligand is necessar…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €100k awarded to the consortium. The project runs over approximately 4 years from 2011-08-01 to 2015-07-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from LT
see all →- SustAInLivWork — Centre of Excellence of AI for Sustainable Living and Working101059903 · HORIZON · €14.7M
- SUPER PV — CoSt redUction and enhanced PERformance of PV systems792245 · H2020 · €9.9M
- Forest 4.0 — Creation of the centre of excellence in smart forestry101059985 · HORIZON · €9.9M
- FemtoSurf — Functional surface treatments using ultra-short pulse laser system FemtoSurf825512 · H2020 · €7.0M
- GIFFT — Sustainable Glass Industry with Fuel-Flexible Technology101122257 · HORIZON · €4.5M
- EnergyKeeper — Keep the Energy at the right place!731239 · H2020 · €4.0M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the MC-CIG funding scheme.
- What is the EU contribution?
- The European Commission contributes €100k toward a total project budget of €100k.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by VILNIAUS UNIVERSITETAS (LT).
- What is the project timeline?
- The project runs from 2011-08-01 to 2015-07-31 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 293476.